New ALS drug trial aims to slow disease progression
NCT ID NCT07325591
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the experimental drug tazbentetol can slow the progression of ALS, a disease that weakens muscles and affects movement. About 430 adults with ALS will receive either the drug or a placebo. The main goal is to see if tazbentetol helps maintain daily functioning, like walking and talking, over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a brain disease change behavior years before diagnosis?
- Can a cancer drug slow ALS? a trial aims to find out
- Can conversation unlock clues to ALS speech decline?
- Could a simple Pre-Tube ritual ease feeding problems in ALS?
- Can tracking brain changes over time unlock the secrets of frontotemporal dementia?
- A muscle test in the thigh may reveal how ALS attacks the body